Key result
Drug-eluting stents showed no difference in target vessel revascularization, death, myocardial infarction, stroke, or stent thrombosis at 12 months compared to bare-metal stents.
Why the study?
The superiority of drug-eluting stents over bare-metal stents for treatment of saphenous vein graft lesions is controversial.
Do drug-eluting stents reduce target vessel revascularization compared to bare-metal stents in patients undergoing saphenous vein graft percutaneous coronary intervention?
Observational (n=174)
Do drug-eluting stents reduce target vessel revascularization compared to bare-metal stents in patients undergoing saphenous vein graft percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Second-generation drug-eluting stents showed no significant difference in target vessel revascularization or hard clinical outcomes compared to bare-metal stents in saphenous vein graft interventions.
Background: Superiority of drug-eluting stents (DES) over bare-metal stents (BMS) for treatment of saphenous vein graft (SVG) lesions is controversial. Methods: This is an observational study comparing the incidence of target vessel revascularization, allcause death, myocardial infarction (MI), stroke and stent thrombosis in patients who underwent SVG percutaneous coronary intervention, using DES versus BMS. Results: Out of 174 cases of SVG percutaneous coronary intervention; 87 received BMS, 66 received DES and 21 received no stents. The majority (94%) of the DES were second generation. There was no difference in target vessel revascularization at 12 months. On multivariate analysis the only predictor of major adverse cardiovascular event was stent length >20 mm. Conclusion: There was no difference in the incidence of death, MI, stroke or stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Mazhar et al. (2015) conducted an observational in Saphenous vein graft (SVG) lesions (n=174). Drug-eluting stents vs. Bare-metal stents was evaluated on Target vessel revascularization. Drug-eluting stents showed no difference in target vessel revascularization, death, myocardial infarction, stroke, or stent thrombosis at 12 months compared to bare-metal stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: